PropertyValue
nif:beginIndex
  • 0 (xsd:integer)
nif:broaderContext
nif:endIndex
  • 156 (xsd:integer)
nif:isString
  • 5) Will gp120 adapt to different CCR5 inhibitors by a similar pathway, or by alternative mutations for each drug (i.e., will cross resistance be a problem)?
rdf:type